Digoxin, the active cardiac glycoside in Digoxin, is prescribed for selected cases of chronic heart failure and atrial fibrillation. It can strengthen cardiac contraction and slow conduction through the atrioventricular node, helping selected patients with symptoms or heart-rate control.
Digoxin is a prescription cardiac glycoside. This class of medicine affects both the strength of the heartbeat and the speed of electrical conduction through the heart. Digoxin Tablets may be used in selected patients with chronic cardiac failure, including congestive cardiac failure, and in atrial fibrillation when control of the ventricular rate is needed.
The active substance is digoxin, a cardiac glycoside. Digoxin Tablets contain digoxin; the exact amount per tablet and any additional ingredients are not specified here.
Digoxin may have a role in chronic cardiac failure when the heart has reduced pumping ability or ventricular dilatation. It can increase myocardial contractility, meaning the force with which the heart muscle contracts.
In atrial fibrillation, digoxin may help slow the passage of electrical signals through the atrioventricular node. This can reduce the ventricular rate in selected patients. The choice depends on the rhythm pattern, activity level, heart-failure status and other rate-control options already prescribed.
Patients with ventricular dilatation, chronic cardiac failure or atrial fibrillation may be considered for digoxin when a clinician judges that its expected benefit outweighs its risks.
Medsafe describes digoxin as a medicine requiring careful clinical use because small changes in exposure can have significant effects [1].
The digoxin dose is individualised. Some patients receive a maintenance dose from the start, while others may receive a loading dose when rapid achievement of therapeutic exposure is clinically appropriate.
A maintenance dose is taken regularly to maintain the intended exposure. A loading dose uses a larger total amount over a limited period and is not automatically required. Poorly selected loading can increase the risk of digoxin toxicity.
Kidney function, age, body size, previous digoxin exposure, electrolyte levels and other medicines influence dose selection. A clinician may change the maintenance amount after a blood test, symptom review, ECG assessment or change in kidney function.
Food, antacids and mineral supplements can affect the timing or absorption of some medicines. Ask for a product-specific spacing plan before adding an over-the-counter supplement.
This medicine may not be suitable if you have a known allergy to digoxin, certain abnormal heart rhythms, heart block, substantially reduced kidney function, low potassium or magnesium, high calcium, or previous digoxin toxicity. Extra care is needed if you are pregnant or breastfeeding, have unexplained fainting or weakness, or take medicines that can affect digoxin levels or heart conduction.
Digoxin side effects can involve the digestive system, nervous system, vision and heart rhythm. The risk rises when digoxin accumulates or when kidney function, hydration, electrolytes or interacting medicines change.
Possible adverse effects include:
Mild nausea alone does not prove toxicity, but new symptoms after a dose change deserve timely review. Yellow or blurred vision together with nausea, poor appetite or unusual weakness is a useful warning pattern that should prompt medical advice.
Digoxin toxicity may cause high digoxin levels, but symptoms and clinical findings matter as well. A blood result alone does not establish the diagnosis. Clinicians consider the timing of the sample, symptoms, kidney function, electrolytes and ECG findings.
Warning signs can include persistent vomiting, severe diarrhoea, marked weakness, confusion, fainting, new visual changes, a very slow pulse or an irregular heartbeat.
Digoxin can contribute to heart block or other clinically significant rhythm disturbances. Heart block means that electrical signals do not pass normally through the heart’s conduction system.
Seek urgent medical care for fainting, severe breathlessness, chest pain, severe confusion, collapse or a very slow or irregular pulse. Do not wait for a routine appointment when these symptoms are severe.
Digoxin works through two linked cardiac effects. It can make each contraction stronger and can slow electrical conduction through the atrioventricular node.
Digoxin inhibits the sodium-potassium ATPase pump in heart muscle cells. This changes sodium movement across the cell membrane and affects calcium handling inside the cell. More available calcium can support a stronger contraction, a process called positive inotropy.
A simple analogy is a stronger squeeze from the same pump. The effect does not rebuild damaged heart muscle, and it does not guarantee that heart failure symptoms will disappear.
Medsafe describes digoxin as having a narrow therapeutic margin, meaning the useful concentration and harmful concentration may be close together [2].
Digoxin also increases vagal influence on the atrioventricular node. The atrioventricular node acts as an electrical gateway between the upper and lower chambers of the heart. Slower passage through this gateway can reduce the ventricular rate in selected atrial fibrillation cases.
Digoxin does not restore normal rhythm in every heart rhythm disorder. Its effect on heart rate may also differ between rest and physical activity, so the clinical setting matters.
Several practical mistakes can increase risk or make treatment appear ineffective:
Digoxin belongs to the cardiac glycosides. Other heart rhythm treatments work through different mechanisms and may be selected according to the rhythm, heart-failure status, kidney or liver function, comorbidities and other medicines.
| Treatment approach | Main pharmacological role | Key monitoring consideration |
|---|---|---|
| Digoxin | Strengthens contraction and slows AV-node conduction | Kidney function, electrolytes, ECG and symptoms |
| Digitoxin | Cardiac glycoside with different elimination characteristics | Liver function, interactions and clinical response |
| Other heart-rate treatments | Reduce conduction or alter rhythm through different pathways | Rhythm type, blood pressure, pulse and comorbidities |
Digitoxin is another cardiac glycoside, but its elimination profile differs from digoxin. The two substances should not be treated as interchangeable. Substitution requires a deliberate prescribing decision and a new monitoring plan.
Heart rhythm treatments may target rate control, rhythm conversion or prevention of complications associated with the arrhythmia. Digoxin mainly provides rate-control and positive-inotropic effects in selected clinical situations.
The best option depends on the person’s cardiac findings rather than on the medicine name alone.
In clinical practice, doctors often treat digoxin as a medicine that rewards precise prescribing rather than rapid self-adjustment. The useful effect may be gradual, while toxicity can emerge after dehydration, illness, kidney-function decline or an interaction.
A cardiology or primary-care review commonly considers:
Doctors also distinguish symptom improvement from correction of the underlying heart disease. Digoxin may support cardiac treatment without replacing management of blood pressure, valve disease, coronary disease or the cause of atrial fibrillation.
Digoxin is a cardiac glycoside that can strengthen contraction and slow atrioventricular-node conduction. Digitoxin is another cardiac glycoside, but its elimination pattern differs, so the two substances are not interchangeable. Other heart-rate treatments use different pharmacological mechanisms and may suit different rhythm or heart-failure profiles. The 2018 NICE guideline supports selecting treatment according to clinical context rather than treating all medicines in this group as equivalent [3].
Do not increase the amount independently if symptoms or heart-rate control do not improve. A clinician may need to review the diagnosis, rhythm, kidney function, electrolytes, ECG and interacting medicines. The 2024 New Zealand Formulary and Medsafe principles support reassessing treatment when response is inadequate or adverse effects appear, rather than making an unsupervised dose change. Seek urgent care for severe breathlessness, chest pain, fainting or collapse.
Fainting, severe breathlessness, chest pain, collapse, severe confusion or a very slow or irregular pulse require urgent medical assessment. Persistent vomiting, marked weakness, new visual disturbance or severe dizziness can also indicate possible digoxin toxicity and need prompt advice. The 2002 WHO guidance identifies medicine-related toxicity as a clinical problem requiring recognition of symptoms alongside treatment and laboratory information [4]. Do not take an extra dose while trying to correct symptoms.
Discuss kidney function, heart rhythm, ECG findings, potassium, magnesium, calcium, previous digoxin exposure and every current medicine. Include amiodarone, diltiazem, verapamil, diuretics, antacids, supplements and herbal products in the review. The prescriber may also consider age, body size, dehydration risk and previous fainting. Medsafe’s 2024 safety information supports medication reconciliation when medicines with narrow safety margins are prescribed [5].
Pregnancy and breastfeeding require an individual review of the expected benefit, maternal condition and possible infant exposure. Do not start, stop or change digoxin during pregnancy without a prescribing decision. A clinician may consider maternal heart function, rhythm, kidney function and the dose required to maintain control. The FDA’s 2022 prescribing information for digoxin advises that pregnancy and lactation decisions should be based on clinical need and appropriate monitoring.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Masterton, took digoxin at his prescribed dose for several months as part of treatment for a heart condition. He said his resting pulse felt more controlled, although he needed repeat blood tests after another medicine was added. He found the monitoring inconvenient but appreciated having the dose reviewed rather than guessing.
Levin, took digoxin at the prescribed dose for the duration advised by his clinician and described improvement in breathlessness after his cardiac treatment was adjusted. He also reported nausea during an illness with poor fluid intake. The symptoms settled after urgent clinical advice and a treatment review, and he said dehydration had been an easy detail to overlook.
Wellington, had used digoxin at the prescribed dose alongside other heart medicines for the duration advised by his clinician. He noticed occasional dizziness and a slower pulse after a new rate-control medicine was introduced. The combination was reviewed, and he learned to report pulse changes instead of simply skipping tablets.
Ashburton, took digoxin at the prescribed dose as part of his daily routine but was unsettled by blurred vision and reduced appetite. He sought prompt advice rather than taking another dose to compensate for a missed tablet. His experience reinforced the value of reporting new symptoms early.
